• Enabling the possibility of
    bone marrow transplantation
    for practically all patients in need

  • Unprecedented

  • Pioneering

Gamida Cell is building a pipeline of curative cellular and immune treatments for cancer and orphan genetic diseases.

One Technology:
Many Applications

Gamida Cell’s pipeline of products is based on the company’s proprietary NAM technology which increases the population of functional cells in culture.

This technology is being applied to various cell types, to develop a pipeline of curative treatments for a wide range of conditions including cancer, genetic hematological diseases such as sickle cell disease and thalassemia, bone marrow failure syndromes such as aplastic anemia and genetic metabolic diseases.

Innovative Treatments

  • NiCord®


    A Breakthrough Therapy Designation for Leukemia and Lymphoma

  • CordIn™


    A Curative Treatment for Rare Genetic Diseases

  • NAM-NK Cells

    NAM-NK Cells

    Immunotherapy for Blood and Solid Cancers

Latest Updates

Gamida Cell Announces Publication of Positive Clinical Outcomes from NiCord-Transplanted Patients in the Journal of Biology of Blood and Marrow Transplantation
Apr. 20, 2017
Gamida Cell Receives Additional EMA Orphan Drug Designation for NiCord® in Haematopoietic Stem Cell Transplantation (HSCT)
Mar. 23, 2017
Gamida Cell Announces First Patient Transplanted in Phase 3 Registration Study of NiCord for Blood Cancers
Feb. 28, 2017